Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
This work was supported by the Fondation Coeur et Recheche, Fédération Française de Cardiologie and Assistance Publique–Hôpitaux de Marseille. 

F.T. has received support for attending meetings from Astra‐Zeneca and Boerhinger‐Ingelheim. C.D. has received grants and consulting fees from Bioserenity. J.A. has received grants and consulting fees from Bioserenity, Bayer, and Biotronik; consulting fees from Bayer, Novartis, Bristol‐Myers Squibb, Astra‐Zenzca, Servier, Boerhinger‐Ingelheim, Biotronik, and Bioserenity; honoraria for lectures from Bayer, Novartis, and Astra‐Zeneca; and support for attending meetings from Bayer and Bristol‐Myers Squibb. J.C. has received honoraria for lectures from Janssen, Novartis, Pfizer, and Bayer; consulting fees from Boerhinger‐Ingelheim and Janssen; and support for attending meetings from Bayer and Pfizer. The remaining authors have no disclosures to report. 

